Aptose Biosciences Inc. (TSX:APS)
Canada · Delayed Price · Currency is CAD 2.400
0.00 (0.00%)
Inactive · Last trade price on Jul 3, 2026
Aptose Biosciences Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Assets
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | 4.11 | 4.1 | 6.71 | 9.25 | 36.97 | 39.11 |
Short-Term Investments | - | - | - | - | 9.99 | 40.01 |
Cash & Short-Term Investments | 4.11 | 4.1 | 6.71 | 9.25 | 46.96 | 79.13 |
Cash Growth | -13.45% | -38.93% | -27.51% | -80.30% | -40.65% | -35.35% |
Other Current Assets | 2.05 | 2.35 | 2.82 | 2.64 | 2.56 | 2.61 |
Total Current Assets | 6.16 | 6.45 | 9.53 | 11.89 | 49.52 | 81.74 |
Net Property, Plant & Equipment | 0.07 | 0.18 | 0.6 | 1.1 | 1.51 | 0.79 |
Other Long-Term Assets | 4.5 | 3.39 | - | - | - | - |
Total Assets | 10.72 | 10.01 | 10.13 | 12.99 | 51.03 | 82.53 |
Liabilities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Accounts Payable | 3.81 | 2.91 | 1.26 | 6.05 | 6.33 | 1.7 |
Accrued Expenses | 7.35 | 6.2 | 2.77 | 8.83 | 5.66 | 6.02 |
Current Portion of Leases | 0.08 | 0.19 | 0.43 | 0.39 | 0.3 | 0.46 |
Other Current Liabilities | 1.29 | 0.86 | 0.02 | - | - | - |
Total Current Liabilities | 11.24 | 9.31 | 4.46 | 15.27 | 12.28 | 8.17 |
Long-Term Debt | 32.87 | 27.02 | 10 | - | - | - |
Long-Term Leases | - | - | 0.19 | 0.62 | 1 | 0.12 |
Total Long-Term Liabilities | 34.16 | 27.87 | 10.21 | 0.62 | 1 | 0.12 |
Total Liabilities | 45.4 | 37.18 | 14.67 | 15.89 | 13.29 | 8.29 |
Shareholders' Equity
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Common Stock | 459.77 | 459.77 | 457.4 | 444.81 | 437.52 | 437.39 |
Additional Paid-in Capital | 83.94 | 83.81 | 83.34 | 72.15 | 68.87 | 63.67 |
Accumulated Other Comprehensive Income | -4.32 | -4.32 | -4.32 | -4.32 | -4.32 | -4.32 |
Retained Earnings | -574.07 | -566.44 | -540.97 | -515.54 | -464.33 | -422.51 |
Shareholders' Equity | -34.67 | -27.17 | -4.54 | -2.9 | 37.74 | 74.24 |
Total Liabilities & Equity | 10.72 | 10.01 | 10.13 | 12.99 | 51.03 | 82.53 |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Total Debt | 32.95 | 27.21 | 10.62 | 1.02 | 1.3 | 0.57 |
Net Cash (Debt) | -28.85 | -23.12 | -3.91 | 8.24 | 45.66 | 78.55 |
Net Cash Growth | - | - | - | -81.96% | -41.88% | -35.25% |
Net Cash Per Share | -11.30 | -9.45 | -5.60 | 36.58 | 222.68 | 396.80 |
Book Value | -34.67 | -27.17 | -4.54 | -2.9 | 37.74 | 74.24 |
Book Value Per Share | -13.58 | -11.10 | -6.50 | -12.88 | 184.07 | 374.99 |
Tangible Book Value | -34.67 | -27.17 | -4.54 | -2.9 | 37.74 | 74.24 |
Tangible Book Value Per Share | -13.58 | -11.10 | -6.50 | -12.88 | 184.07 | 374.99 |